MetLife Investment Management LLC Makes New Investment in Metsera Inc. $MTSR

Key Points

• MetLife Investment Management LLC acquired 9,342 shares of Metsera Inc. ($MTSR) valued at approximately $254,000 during the first quarter of the year.
• Brokerages have set new price targets for Metsera, with Bank of America raising its target from $45.00 to $50.00 and Wells Fargo initiating coverage with a $65.00 target and an "overweight" rating.
• The stock currently has a buy rating from five equities research analysts, with an average price target of $59.00, while also showing significant price volatility with a 52-week range of $12.30 to $47.40.

MetLife Investment Management LLC purchased a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 9,342 shares of the company's stock, valued at approximately $254,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Alphabet Inc. acquired a new stake in Metsera in the 1st quarter worth $135,059,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Metsera during the 1st quarter valued at about $78,748,000. Invesco Ltd. acquired a new stake in shares of Metsera during the 1st quarter valued at about $271,000. Jennison Associates LLC acquired a new stake in shares of Metsera during the 1st quarter valued at about $9,679,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Metsera during the 1st quarter valued at about $3,410,000.

Analyst Ratings Changes

Several analysts have recently weighed in on MTSR shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Wells Fargo & Company started coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Bank of America lifted their target price on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Leerink Partnrs upgraded shares of Metsera to a "strong-buy" rating in a research report on Tuesday. Finally, Leerink Partners started coverage on shares of Metsera in a research report on Tuesday. They set an "outperform" rating and a $77.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. According to data from MarketBeat, Metsera has a consensus rating of "Buy" and a consensus target price of $63.50.

Metsera Trading Down 3.0%

MTSR stock traded down $1.12 during trading on Friday, hitting $36.13. 1,004,281 shares of the stock traded hands, compared to its average volume of 1,037,312. Metsera Inc. has a one year low of $12.30 and a one year high of $47.40. The company has a 50 day simple moving average of $35.37 and a 200 day simple moving average of $28.81.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.